Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Spiriva May Be UPLIFTed By Positive Trial Results After JAMA Bashing

This article was originally published in The Pink Sheet Daily

Executive Summary

BI, Pfizer rebut assertion inhaled anticholinergics carry cardio risk.
Advertisement

Related Content

Spiriva’s “All-Clear” On CV Safety From FDA Could Raise Bar For COPD Candidates
Spiriva’s “All-Clear” On CV Safety From FDA Could Raise Bar For COPD Candidates
Pfizer/Boehringer Ingelheim’s Spiriva Linked To Stroke In FDA MedWatch Alert
Pfizer/Boehringer Ingelheim’s Spiriva Linked To Stroke In FDA MedWatch Alert

Topics

Advertisement
UsernamePublicRestriction

Register

PS068397

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel